Project Grant R01CA316855
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $767K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute, within the Department of Health and Human Services, awarded Dana-Farber Cancer Institute, Inc. $718,275 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate context-specific pathway dependencies for nuclear envelope proteins in brain cancer. The research addresses how nuclear envelope-associated proteins perform distinct biochemical functions across different cellular contexts in central nervous system cancers. The project uses an...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $134,919 on April 14, 2026, under the Cancer Research Manpower program (CFDA 93.398) to establish ethical standards for informed consent and counseling in multi-cancer early detection testing. Dr. Eric Blackstone, a bioethics research fellow, will conduct three coordinated research aims. Aim 1 evaluates patient comprehension of key multi-cancer early detection information and patient experiences with informed consent and...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $432,050 on August 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop peptide-MHC pseudotyped retroviral vectors for in vivo gene delivery to antigen-specific T cells as a novel cancer immunotherapy approach. The work addresses a gap in current cancer immunotherapies by combining attributes of CAR-T cell therapies with tumor-infiltrating lymphocyte and immune checkpoint blockade...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Beth Israel Deaconess Medical Center, Inc. $524,110 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393, Assistance Listing Project Grant R01CA314254). The award funds research on one-ended break repair mechanisms in mammalian cells, specifically investigating how cells repair DNA damage at broken replication forks and double-strand...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $721,653 on June 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate protein O-mannosylation as a therapeutic vulnerability in KIAA1549-BRAF-driven pediatric low-grade glioma. The research program combines molecular mechanistic studies with in vivo mouse models to validate whether O-mannosylation of the KIAA1549 fusion protein is necessary for gliomagenesis and to evaluate POMT complex...
- The National Cancer Institute awarded The Children's Hospital Corporation (Boston Children's Hospital) $738,698 on August 12, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the molecular and genomic basis of transposon-associated alternative splicing (TEAS) in human cancers. The research integrates genomic, transcriptomic, and functional analyses across three aims. The first comprehensively characterizes TEAS events using bulk and single-cell long-read RNA...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $2,498,737 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify mechanisms of malignant transformation in monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) and develop therapies for early interception of progression to multiple myeloma. The award funds three integrated research projects and two supporting cores. Project 1 discovers, models,...